{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:23:20Z","timestamp":1780514600109,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10072-018-3628-3","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T17:28:17Z","timestamp":1541006897000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-2945","authenticated-orcid":false,"given":"Maria Laura Ester","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Riboldazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Versino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"3628_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4236\/apd.2015.43008","volume":"4","author":"HP Yadav","year":"2015","unstructured":"Yadav HP, Li Y (2015) The development of treatment for Parkinson\u2019s disease. Adv Parkinsons Dis 4:59\u201378","journal-title":"Adv Parkinsons Dis"},{"key":"3628_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","volume":"25","author":"AH Schapira","year":"2011","unstructured":"Schapira AH (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25:1061\u20131071","journal-title":"CNS Drugs"},{"key":"3628_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fncel.2015.00025","volume":"9","author":"F Gardoni","year":"2015","unstructured":"Gardoni F, Bellone C (2015) Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and addiction diseases. Front Cell Neurosci 9:25","journal-title":"Front Cell Neurosci"},{"key":"3628_CR4","doi-asserted-by":"publisher","first-page":"b5614","DOI":"10.1136\/bmj.b5614","volume":"340","author":"DG Grosset","year":"2010","unstructured":"Grosset DG, Macphee GJ, Nairn M, Guideline Development Group (2010) Diagnosis and pharmacological management of Parkinson\u2019s disease: summary of SIGN guidelines. DG BMJ 340:b5614","journal-title":"DG BMJ"},{"issue":"2","key":"3628_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.17925\/ENR.2009.04.01.25","volume":"4","author":"A Antonini","year":"2009","unstructured":"Antonini A (2009) Nonmotor symptoms in Parkinson\u2019s disease. Eur Neurol Rev 4(2):25\u201327","journal-title":"Eur Neurol Rev"},{"issue":"Suppl 3","key":"3628_CR6","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1007\/s00415-009-5240-1","volume":"256","author":"A Park","year":"2009","unstructured":"Park A, Stacy M (2009) Non-motor symptoms in Parkinson\u2019s disease. J Neurol 256(Suppl 3):S293\u2013S298","journal-title":"J Neurol"},{"key":"3628_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","volume":"25","author":"I Shoulson","year":"1975","unstructured":"Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144","journal-title":"Neurology"},{"key":"3628_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA (2009) Levodopa: past, present. and future Eur Neurol 62:1\u20138","journal-title":"and future Eur Neurol"},{"key":"3628_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/13543784.2012.651457","volume":"21","author":"F Blandini","year":"2012","unstructured":"Blandini F, Armentero MT (2012) New pharmacological avenues for the treatment of L-dopa-induced dyskinesias in Parkinson\u2019s disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 21:153\u2013168","journal-title":"Expert Opin Investig Drugs"},{"issue":"7 Suppl 2","key":"3628_CR10","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","volume":"67","author":"C Caccia","year":"2006","unstructured":"Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L et al (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl 2):S18\u2013S23","journal-title":"Neurology"},{"key":"3628_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","volume":"17","author":"M Onofrj","year":"2008","unstructured":"Onofrj M, Bonanni L, Thomas A (2008) An expert opinion on safinamide in Parkinson\u2019s disease. Expert Opin Investig Drugs 17:1115\u20131125","journal-title":"Expert Opin Investig Drugs"},{"key":"3628_CR12","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.2174\/156802611798184355","volume":"11","author":"C Binda","year":"2011","unstructured":"Binda C, Milczek EM, Bonivento D, Wang J, Mattevi A, Edmondson DE (2011) Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Curr Top Med Chem 11:2788\u20132796 Review","journal-title":"Curr Top Med Chem"},{"key":"3628_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nurt.2006.11.011","volume":"4","author":"RG Fariello","year":"2007","unstructured":"Fariello RG (2007) Safinamide. Neurotherapeutics 4:110\u2013116 Review","journal-title":"Neurotherapeutics"},{"key":"3628_CR14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1517\/14656566.2010.511612","volume":"11","author":"AH Schapira","year":"2010","unstructured":"Schapira AH (2010) Safinamide in the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother 11:2261\u20132268","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 2","key":"3628_CR15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3949\/ccjm.79.s2a.01","volume":"79","author":"C Singer","year":"2012","unstructured":"Singer C (2012) Managing the patient with newly diagnosed Parkinson disease. Cleve Clin J Med 79(Suppl 2):S3\u2013S7","journal-title":"Cleve Clin J Med"},{"key":"3628_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","volume":"19","author":"L Gregoire","year":"2013","unstructured":"Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T (2013) Safinamide reduces dyskinesias and prolongs L-dopa antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 19:508\u2013514","journal-title":"Parkinsonism Relat Disord"},{"key":"3628_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-015-0389-7","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED (2015) Safinamide: first global approval. Drugs 75:705\u2013711","journal-title":"Drugs"},{"key":"3628_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 29:229\u2013237","journal-title":"Mov Disord"},{"key":"3628_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, the Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord 29:1273\u20131280","journal-title":"Mov Disord"},{"key":"3628_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10072-018-3272-y","volume":"39","author":"F Mancini","year":"2018","unstructured":"Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, Comi C (2018) Real life evaluation of safinamide effectiveness in Parkinson\u2019s disease. Neurol Sci 39:733\u2013739","journal-title":"Neurol Sci"},{"issue":"2","key":"3628_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.17925\/ENR.2015.10.02.176","volume":"10","author":"U Bonuccelli","year":"2015","unstructured":"Bonuccelli U (2015) Effects of safinamide on motor complications and pain in advancing Parkinson\u2019s disease \u2013 post hoc analyses of pivotal trials. European Neurological Review 10(2):176\u2013181","journal-title":"European Neurological Review"},{"key":"3628_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JPD-160911","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, Barone P, Bonizzoni E, Sardina M (2017) Effects of safinamide on pain in fluctuating Parkinson\u2019s disease patients: a post-hoc analysis. Journal of Parkinson\u2019s Disease 7:95\u2013101","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"2017","key":"3628_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, M\u00fcller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C (2017) Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. Journal of Parkinson\u2019s Disease 7(2017):629\u2013634","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"3628_CR24","unstructured":"XADAGO\u00ae (safinamide) Summary of Product Characteristics"},{"key":"3628_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2008.02212.x","volume":"15","author":"KR Chaudhuri","year":"2008","unstructured":"Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15:2\u20137","journal-title":"Eur J Neurol"},{"key":"3628_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2016.10.020","volume":"34","author":"I Cova","year":"2017","unstructured":"Cova I, Di Battista ME, Vanacore N, Papi CP, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S (2017) Validation of the Italian version of the nonmotor symptoms scale for Parkinson\u2019s disease. Parkinsonism Relat Disord 34:38\u201342","journal-title":"Parkinsonism Relat Disord"},{"key":"3628_CR27","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314\u20132324","journal-title":"Mov Disord"},{"issue":"9","key":"3628_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fneur.2018.00138","volume":"12","author":"T Prell","year":"2018","unstructured":"Prell T (2018) Structural and functional brain patterns of non-motor syndromes in Parkinson\u2019s disease. Front Neurol 12(9):138","journal-title":"Front Neurol"},{"key":"3628_CR29","doi-asserted-by":"publisher","unstructured":"Liguori C, Stefani A, Ruffini R, Mercuri NB, Pierantozzi M (2018) Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson\u2019s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord. doi: \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.033","DOI":"10.1016\/j.parkreldis.2018.06.033"},{"key":"3628_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.sleep.2017.09.017","volume":"41","author":"C Liguori","year":"2018","unstructured":"Liguori C, Mercuri NB, Stefani A, Pierantozzi M (2018) Effective treatment of restless legs syndrome by safinamide in Parkinson\u2019s disease patients. Sleep Med 41:113\u2013114","journal-title":"Sleep Med"}],"updated-by":[{"DOI":"10.1007\/s10072-018-3658-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3628-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:15:55Z","timestamp":1572466555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3628"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3628-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10072-018-3658-x","asserted-by":"object"}]},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"1 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article contains an error in Table\u00a02. The Authors realized that they submitted the previous version of Table\u00a02. The correct version of Table 2 is shown here.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}